S10 Ep44: Curigliano on the DESTINY-Breast06 Trial in HER2-Low and -Ultralow Metastatic Breast Cancer

OncLive® On Air - Podcast készítő OncLive® On Air

Podcast artwork

Dr Curigliano discusses the DESTINY-Breast06 trial of trastuzumab deruxtecan in patients with HER2-low or HER2-ultralow metastatic breast cancer.

Visit the podcast's native language site